Allos Therapeutics, Inc. (ALTH) Saturday revealed results from two pralatrexate studies, indicating that pralatrexate has activity when administered as a single agent in patients with CTCL and in combination with gemcitabine in patients with lymphoma.
Pralatrexate is a novel targeted antifolate designed to accumulate preferentially in cancer cells. Based on preclinical studies, the company believes that pralatrexate selectively enters cells expressing RFC-1, a protein that is over expressed on cancer cells compared to normal cells.
Once inside cancer cells, pralatrexate is efficiently polyglutamylated, which leads to high intracellular drug retention.
Pablo Cagnoni, Chief Medical Officer of Allos said, "The studies will continue with the objective of determining the optimal dose and schedule for these indications."
The results presented at the American Society of Hematology reports includes interim data from a Phase 1 trial of pralatrexate as a single agent in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Data from a Phase 1/2a trial of pralatrexate in combination with gemcitabine in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's lymphoma were also reported.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.